Abstract
The cantharidinimide derivatives, 5a-h, including sulfanilamides containing pyrimidyl, pyrazinyl, hydrogen, thiazolyl, and oxazolyl groups were synthesized. Modification of cantharidinimide by means of the reaction of activated aziridine ring opening led to the discovery of a novel class of antitumor compounds. The analogues 10i-k, 11l-n, 12o-p, and 16q-s were obtained from treating cantharidinimide 6 and analogues (7, 8, and 13) with activated aziridines, which produced a series of ring-opened products including normal and abnormal types. Some of these compounds showed cytotoxic effects in vitro against HL-60, Hep3B, MCF7, and MDA-MB-231 cancer cells. The most potent cytostatic compound, N-cantharidinimido-sulfamethazine (5a), exhibited anti-HL-60 and anti-Hep3B cell activities. Two compounds 5g and 5h displayed slight effects on the Hep3B cell line, while the other compounds produced no response in these four cell lines.
References
Jul 1, 1977·Journal of the National Cancer Institute·J FoghT Orfeo
Dec 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·Y M Li, J E Casida
Sep 1, 1989·Journal of Ethnopharmacology·G S Wang
Jan 1, 1989·Journal of Pharmaceutical Sciences·W G Walter
Sep 20, 1993·FEBS Letters·R E Honkanen
Oct 23, 1997·Journal of the National Cancer Institute·K WosikowskiS E Bates
Feb 7, 2001·Bioorganic Chemistry·L Pen-YuanW Leng-Fang
Oct 27, 2001·Archives of Dermatology·L MoedM W Chang
Jan 30, 2002·Bioorganic & Medicinal Chemistry Letters·Adam McCluskeyJennette A Sakoff
Jun 1, 1964·The Journal of Investigative Dermatology·R H DECKER
Mar 31, 2004·Bioorganic & Medicinal Chemistry Letters·Matthew E HartAdam McCluskey
Jul 17, 2004·Chemical & Pharmaceutical Bulletin·Lun-Huei LinPen-Yuan Lin
Feb 16, 2005·Biochemical Pharmacology·Thomas EfferthBernd Kaina
Sep 11, 2009·European Journal of Medicinal Chemistry·Elena L Luzina, Anatoliy V Popov
Mar 25, 2010·Cancer Science·Wei LiXiao Han
Sep 21, 2010·European Journal of Medicinal Chemistry·Elena L Luzina, Anatoliy V Popov
Jan 29, 2011·International Journal of Oncology·Wen-Wen HuangJai-Sing Yang
Oct 18, 2011·Toxicon : Official Journal of the International Society on Toxinology·Inés S Sánchez-BarbudoRafael Mateo
Apr 28, 2012·European Journal of Medicinal Chemistry·Elena L Luzina, Anatoliy V Popov
Jul 17, 2012·European Journal of Medicinal Chemistry·Mark TarletonAdam McCluskey
Nov 6, 2012·Chemical & Pharmaceutical Bulletin·Ing-Jy TsengPen-Yuan Lin
May 28, 2013·Journal of Ethnopharmacology·Akalesh Kumar Verma, Surya Bali Prasad
Jul 3, 2013·Chemical Biology & Drug Design·Carlos E Puerto GalvisVladimir V Kouznetsov
Nov 16, 2013·Biochemical Pharmacology·Onat KadiogluThomas Efferth
May 14, 2014·International Journal of Oncology·Te-Chun HsiaJing-Gung Chung
Oct 24, 2014·International Journal of Oncology·Yu-Ping HsiaoJing-Gung Chung
Nov 18, 2014·Journal of Fluorine Chemistry·Elena L Luzina, Anatoliy V Popov
Nov 27, 2014·Journal of Dental Research·Y XiA M Fribley
May 15, 2015·The American Journal of Chinese Medicine·Chin-Chuan SuChun-Fa Huang
Jul 28, 2015·Journal of Fluorine Chemistry·Elena L Luzina, Anatoliy V Popov
Citations
Feb 18, 2017·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Shu-Feng Zhou, Wei-Zhu Zhong
Jan 31, 2020·Biomedical Chromatography : BMC·Yaobo ZengDajian Yang
Aug 4, 2020·Chemistry & Biodiversity·Lei GuoYan Hua
May 8, 2018·Molecular Diversity·Rabia AkhtarSameera Saleem